Abstract
A daily supplement of vitamin E is recommended for the secondary prevention of cardiovascular events in end-stage renal disease patients on maintenance hemodialysis. Vitamin E has been entrusted with therapeutic properties against cardiovascular disease for more than 60 years. Several epidemiological studies and intervention trials have been performed with vitamin E, and some of them showed that it prevents atherosclerosis. For a long time, vitamin E was assumed to act by decreasing the oxidation of low-density lipoproteins, a key step in atherosclerosis initiation. However, at the cellular level vitamin E interferes with smooth muscle cell proliferation, platelet aggregation, monocyte adhesion, and oxidized low-density lipoproteins uptake and cytokine production, all reactions implied in the progression of atherosclerosis. Recent research points out that these effects may be not only the result of the antioxidant activity of vitamin E but also of its distinct molecular actions. These biological properties of vitamin E may allow to design better strategies for primary and secondary prevention of cardiovascular disease, with a potential exploitation of vitamin E supplements in primary and secondary prevention of major adverse cardiovascular events in all uremic patients. In this review, we also outline relevant patents on vitamin E and lipoxygenase inhibitors.
| Original language | English |
|---|---|
| Pages (from-to) | 229-240 |
| Number of pages | 12 |
| Journal | Recent Patents on Inflammation and Allergy Drug Discovery |
| Volume | 5 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Sep 2011 |
Fingerprint
Keywords
- 5-lipoxygenase
- Cardiovascular disease
- Hemodialysis
- Outcomes
- Oxidative stress
- Vitamin E
ASJC Scopus subject areas
- Drug Discovery
- Immunology and Allergy
Cite this
Vitamin E-related inhibition of monocyte 5-lipoxygenase and cardiovascular outcome in maintenance hemodialysis patients. / Manca-di-Villahermosa, Simone; Giacominelli-Stuffler, Roberto; Angelucci, Clotilde B.; Taccone-Gallucci, Massimo; Maccarrone, Mauro.
In: Recent Patents on Inflammation and Allergy Drug Discovery, Vol. 5, No. 3, 09.2011, p. 229-240.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Vitamin E-related inhibition of monocyte 5-lipoxygenase and cardiovascular outcome in maintenance hemodialysis patients
AU - Manca-di-Villahermosa, Simone
AU - Giacominelli-Stuffler, Roberto
AU - Angelucci, Clotilde B.
AU - Taccone-Gallucci, Massimo
AU - Maccarrone, Mauro
PY - 2011/9
Y1 - 2011/9
N2 - A daily supplement of vitamin E is recommended for the secondary prevention of cardiovascular events in end-stage renal disease patients on maintenance hemodialysis. Vitamin E has been entrusted with therapeutic properties against cardiovascular disease for more than 60 years. Several epidemiological studies and intervention trials have been performed with vitamin E, and some of them showed that it prevents atherosclerosis. For a long time, vitamin E was assumed to act by decreasing the oxidation of low-density lipoproteins, a key step in atherosclerosis initiation. However, at the cellular level vitamin E interferes with smooth muscle cell proliferation, platelet aggregation, monocyte adhesion, and oxidized low-density lipoproteins uptake and cytokine production, all reactions implied in the progression of atherosclerosis. Recent research points out that these effects may be not only the result of the antioxidant activity of vitamin E but also of its distinct molecular actions. These biological properties of vitamin E may allow to design better strategies for primary and secondary prevention of cardiovascular disease, with a potential exploitation of vitamin E supplements in primary and secondary prevention of major adverse cardiovascular events in all uremic patients. In this review, we also outline relevant patents on vitamin E and lipoxygenase inhibitors.
AB - A daily supplement of vitamin E is recommended for the secondary prevention of cardiovascular events in end-stage renal disease patients on maintenance hemodialysis. Vitamin E has been entrusted with therapeutic properties against cardiovascular disease for more than 60 years. Several epidemiological studies and intervention trials have been performed with vitamin E, and some of them showed that it prevents atherosclerosis. For a long time, vitamin E was assumed to act by decreasing the oxidation of low-density lipoproteins, a key step in atherosclerosis initiation. However, at the cellular level vitamin E interferes with smooth muscle cell proliferation, platelet aggregation, monocyte adhesion, and oxidized low-density lipoproteins uptake and cytokine production, all reactions implied in the progression of atherosclerosis. Recent research points out that these effects may be not only the result of the antioxidant activity of vitamin E but also of its distinct molecular actions. These biological properties of vitamin E may allow to design better strategies for primary and secondary prevention of cardiovascular disease, with a potential exploitation of vitamin E supplements in primary and secondary prevention of major adverse cardiovascular events in all uremic patients. In this review, we also outline relevant patents on vitamin E and lipoxygenase inhibitors.
KW - 5-lipoxygenase
KW - Cardiovascular disease
KW - Hemodialysis
KW - Outcomes
KW - Oxidative stress
KW - Vitamin E
UR - http://www.scopus.com/inward/record.url?scp=80052832327&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052832327&partnerID=8YFLogxK
U2 - 10.2174/187221311797264892
DO - 10.2174/187221311797264892
M3 - Article
C2 - 21843148
AN - SCOPUS:80052832327
VL - 5
SP - 229
EP - 240
JO - Recent Patents on Inflammation and Allergy Drug Discovery
JF - Recent Patents on Inflammation and Allergy Drug Discovery
SN - 1872-213X
IS - 3
ER -